Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-TRBC1-MMAE
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-TRBC1-MMAE is an experimental antibody-drug conjugate (ADC) comprising a monoclonal antibody against TRBC1, a constant region of the T-cell receptor β-chain expressed clonally in certain T cell leukemias and lymphomas, conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable linker. The anti-TRBC1 antibody specifically targets TRBC1+ cancer cells, allowing internalization and selective delivery of MMAE, which is released intracellularly to disrupt microtubule polymerization, leading to apoptosis of the targeted tumor cell. The drug was developed in a research setting primarily by a team at Johns Hopkins, for the treatment of TRBC1+ T cell malignancies, demonstrating potent and selective killing of TRBC1+ T-cell leukemias and lymphomas in preclinical models[2][3][6].
- Other names
- anti-TRBC1–MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))TRBC1 (T-cell receptor beta constant region 1)
Beyond the preview
Go deeper on anti-TRBC1-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-TRBC1-MMAE.